January 28, 2025 • 17 mins
This episode takes a closer look at pharmaceutical impurities and the ICH guidelines (Q3A-Q3E) that govern their identification, classification, and control. From organic and inorganic impurities to residual solvents, we explore how these unwanted substances can originate, how they're detected using advanced analytical techniques like mass spectrometry, and how acceptable daily intake (ADI) levels are established to ensure patient safety.
We delve into the role of stability testing in managing degradation products and highlight the importance of purge factors in controlling impurities during manufacturing. Computational tools like QSAR models are transforming impurity risk assessments, enabling faster, data-driven predictions of toxicity.
For biopharmaceuticals, managing product-related impurities introduces unique challenges due to their complexity and variability. Guidelines like ICH Q5A and Q6B are critical in ensuring the quality of these therapies, while global harmonization efforts strive to maintain consistent regulatory standards across borders.
Looking ahead, advancements in analytical technology, computational modeling, and global collaboration are shaping a proactive future for impurity control. This deep dive underscores the immense scientific effort and regulatory commitment that ensure medications are safe and effective for patients worldwide.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
(00:00):
All right, ready to dive deep.
(00:02):
Today, it's all about pharmaceuticals,
but not the feel-good kind.
Ah, you mean the stuff we don't want in our meds.
Exactly, impurities.
We've got a great prompt from a listener
wants to unpack those ICH guidelines,
Q3A through Q3E specifically.
Great area to explore.
It's fascinating really how even a perfectly crafted drug
(00:24):
can have, you know,
these tiny bits of unwanted stuff lurking in it.
Okay, so maybe not something you want to think about
with every pill you swallow,
but crucial nonetheless, right, for safety and effectiveness.
Oh, absolutely crucial.
And that's precisely where these ICH guidelines come in.
They're like our rule book really
for making sure medications are safe
and actually do what they're supposed to do.
Okay, so rule book for impurities.
(00:45):
Let's unpack that a bit, shall we?
Yeah.
You mentioned different types of impurities.
What are we talking about here specifically?
Well, you can broadly break them down into a few categories,
organic, inorganic,
and then you've got those residual solvents.
Each one, you know, they pose their own risks
and need their own approach to control.
Makes sense.
I'm picturing, I don't know,
some heavy metal leaching into a drug from the equipment.
(01:07):
Is that a real thing that happens?
It is.
Inorganic impurities, like those heavy metals,
they often come from the manufacturing process itself.
You've also got organic impurities though,
and those might be present in the starting materials.
And then there's the whole degradation thing.
A drug can actually break down over time.
So even more potential impurities to worry about.
(01:27):
Makes you realize how complex this all is.
How do they even find these things?
That's where it gets really interesting.
You know, we're talking super precise analytical techniques
that can zero in and actually quantify these substances,
even when they're at super low levels.
So like finding a needle in a haystack,
but on a molecular level.
Pretty much.
One example is high resolution mass spectrometry.
(01:50):
Incredible tool.
Lets us measure the mass of molecules
with pinpoint accuracy,
so we can even spot tiny variations.
Could be a sign of an impurity.
Super high tech stuff.
So we found an impurity.
Now how do we know if it's a problem?
Like is there a universal too much level?
Or does it depend on the drug?
Definitely not one size fits all.
The ICH guidelines provide a framework,
(02:12):
but there are lots of factors.
Toxicity of the impurity, for example, is huge.
A highly toxic impurity is gonna have
a much lower acceptable limit.
Right, that makes sense.
What about how the drug is taken like daily
versus just once in a while?
That must factor in too.
Absolutely.
Imagine a drug taken daily for a chronic condition
versus like you said, one for a short term illness.
(02:32):
The acceptable limit for say an impurity
in that daily medication is likely gonna be way lower,
because of the longer exposure.
Okay, starting to see how this ties back to patient safety.
It's a real balancing act.
Exactly.
And that's where this concept of acceptable daily intake
comes in, ADI.
It's essentially how much of a specific substance
can be ingested daily over a lifetime without causing harm.
(02:55):
Plays a big role in setting limits.
So how do they calculate those ADIs and safety limits?
Some magic formula.
Not magic, but definitely not guesswork either.
Established methodologies, statistical models,
the whole nine yards to do a really thorough risk assessment.
Our listener actually mentioned statistical validation
in their prompt.
(03:16):
What's that mean here?
It's all about making those assessments
as reliable as we can.
Using statistical methods to analyze data,
identify trends, really build confidence
in those safety limits we're setting.
Sounds super rigorous.
Makes sense though.
Earlier you mentioned drugs breaking down over time.
How has that managed?
Stability testing is key.
(03:37):
Imagine storing samples under different conditions,
temperatures, humidity, light,
and then we analyze them over time to see how they change.
Gives us a real insight into shelf life
and how to store them properly.
Sounds meticulous.
It is, but it impacts safety directly.
A drug that goes bad quickly could be, well, dangerous.
This helps us prevent that.
(03:57):
Okay, let's switch gears for a second.
Listener also asked about purge factors.
What are those all about?
Purge factors.
They're a measure of how effectively we remove impurities
during manufacturing, like quantifying the cleaning power
of each step, you could say.
And of course we calculate and validate those carefully
to make sure the levels are safe in the end.
Interesting.
So it's like each step is a filter,
(04:18):
getting rid of more and more of those impurities.
Precisely.
Now imagine we find a brand new impurity,
something never seen before.
Gotta figure out quickly how risky it is.
That sounds tough.
It is.
That's where QSR comes in,
quantitative structure activity relationship.
QSR.
Okay, sounds a bit sci-fi.
How's that work?
(04:38):
Might sound futuristic,
but it's a real workhorse in toxicology today.
We use computer models to predict
how toxic a substance might be
just based on its chemical structure.
So instead of a ton of experiments,
you can use algorithms to get a first look.
Yep.
It's super valuable when you're dealing
with something brand new and don't have much data,
helps us prioritize.
(04:59):
Amazing.
Technology is changing the game here.
It is.
And it goes even further with all these new
software tools being developed.
They can help us define toxicological classes of impurities
so much more efficiently.
This is fascinating.
Feels like we're just getting started.
It makes you realize how much work goes into
ensuring that our meds are safe.
It's a hidden world, really,
but one that affects all of us.
(05:20):
That's what makes this deep dive so important.
Welcome back to the deep dive.
We've covered some fundamentals,
but now let's get into those real world complexities
like you mentioned.
Exactly.
Biopharmaceuticals, that's what really intrigues me.
Seems like a whole other level
when it comes to controlling impurities.
You're right, they do.
Biopharmaceuticals, you know,
those drugs derive from living organisms.
(05:43):
They tend to be much bigger, more complex molecules.
More complex than, say,
the everyday pills most of us are used to.
Exactly, and that complexity makes them, well,
more prone to a wider variety of impurities.
So we're not just talking about
simple contamination anymore.
Right.
With these biopharmaceuticals,
we've got to consider things like product-related impurities.
Basically, variations of the protein itself
(06:05):
that pop up during manufacturing.
So the protein itself can have, what, little variations?
How does that even happen?
Think of it like this.
The cells making those proteins,
they can make tiny mistakes,
and those mistakes lead to, well,
variations in the final product.
They might have slightly different structures
or some kind of modification.
So even a tiny difference could affect how the drug works.
(06:27):
Wow, how do they even find those variations?
It's like detective work at a molecular level.
We're talking advanced stuff.
Mass spectrometry, for instance,
can measure the mass of these molecules so precisely
we can see even the smallest variations.
And then there's chromatography,
separates the components of the mixture,
lets us zero in on each one.
Like a molecular jigsaw puzzle.
(06:49):
You got it.
Yeah.
And to help us solve that puzzle,
we rely on guidelines like ICH Q5A, R2, and Q6B,
specifically focused on those impurities
in biopharmaceuticals.
These guidelines are like the gift that keeps on giving.
Seems like they're behind every aspect of this process.
They are, really, and they're always evolving, too,
just like our understanding of these drugs
and the techniques we use to analyze them.
(07:10):
Makes sense.
Okay, so we found those product-related impurities,
but then there's still the stability issue, right?
They can change over time, degrade, all that.
Absolutely.
Stability is key, you know?
For any drug, really.
It has to stay safe and effective
throughout its shelf life.
Right, you wouldn't want a medication to, what,
lose its potency or become unsafe
just because it's been sitting around too long?
(07:32):
Exactly.
Yeah.
So that's where stability testing steps in.
Remember those controlled storage conditions,
different temperatures, humidity, light?
That's a big part of it.
We store the samples under those conditions
and analyze them over time, see how they change,
helps us figure out how long they're good for
and how to store them.
Sounds like a pretty involved process.
(07:52):
It is, but it's all about safety, right?
Making sure that those medications are good to go
when patients need them.
And of course, there are guidelines for that, too.
ICH Q1A, R2 is a big one, lays out the framework.
And there's also Q1F from the WHO
that specifically focuses
on active pharmaceutical ingredients.
So those guidelines keep everything consistent
and rigorous to make sure those tests are done right.
(08:12):
Right.
Ultimately, it's all about having that scientific basis
to know how long a drug is good for.
And that's absolutely critical for safety, right?
Making sure that the medications people are taking
are doing what they should be doing.
Now, what happens if a company has to make changes
to the way they manufacture a drug?
Like to make it more efficient or maybe address a problem?
(08:33):
Good question.
That's where change management comes into play.
Another key part of impurity control.
Any change, even a small one,
has the potential to affect the final product,
including its impurity profile.
Because even a small tweak could introduce something new
or change the levels, right?
How do they make sure those changes don't mess things up?
That's where ICH Q5E comes in.
(08:54):
This guideline tells us how to compare
the drug substance or product before and after a change.
The goal is to show that the final product
is essentially the same,
that it still meets those strict standards,
even with those changes.
So like comparing before and after
to see if anything went haywire?
Precisely.
We might compare physical, chemical,
even biological properties,
(09:15):
maybe do more stability studies.
Sometimes we even need new clinical trials,
depending on the change.
Wow, that's really reassuring.
It shows you how seriously they take this whole thing.
Absolutely, and that commitment to quality,
it's at the heart of what we call
a robust pharmaceutical quality system.
That's what ICH Q10 is all about.
It's not just about following the rules.
(09:35):
It's about managing quality in every aspect,
from design to manufacturing to distribution.
The goal, making sure that product quality is consistent
and patients are safe.
Like this huge interconnected system
all working together to keep patients safe.
That's a good way to put it.
And managing impurities,
well, it's a crucial part of that whole system.
Okay, we've covered a lot here.
(09:56):
Biopharmaceuticals, stability testing, managing change,
but I want to circle back to the why behind all this.
The why is always important.
Right, why does all of this matter so much?
What happens if we don't control impurities?
What are the consequences?
That's a big question,
and the answer is pretty straightforward.
Failing to control those impurities
can have serious consequences for patients.
(10:17):
It's easy to forget, right?
Yeah. These impurities are tiny.
We can't even see them, but they can have a real impact.
Exactly.
We've talked about how impurities
can affect how well a drug works,
maybe even making a condition worse.
But in some cases,
they can trigger serious unexpected side effects.
So it could be anything from a mild reaction
to something much worse.
(10:38):
Absolutely.
That's why it's so important for drug companies
and regulatory agencies to get this right.
Every step from the ingredients to the manufacturing
has to be carefully controlled
to keep those harmful impurities out of the drug supply.
It all comes back to those ICH guidelines, right?
Q3A through Q3E, making sure we can identify,
classify, and control those impurities
(10:59):
and all those incredible analytical techniques
that let us see what's really there.
Right. But it's more than just checking boxes.
It's about really understanding the science
and always striving to do better.
Always learning, always improving,
all to protect patients.
That's the key.
This deep dive, it's really pulled back the curtain
on all the science, the regulations,
(11:19):
the ethics that go into making pharmaceuticals.
It's a complex system, but it all comes down
to that commitment to patient wellbeing.
I'm with you.
It's amazing really to think about how much we've learned
about something that most people
probably never think twice about.
But as we've seen, it's incredibly important.
It is.
And as technology keeps advancing
(11:40):
and we learn more and more,
the challenges and opportunities in this field
are only going to get bigger.
That brings us to the next frontier,
the future of impurity control.
I'm excited to see what's coming next.
Me too.
In the next segment, we'll dive
into some of the most exciting developments,
stuff that's shaping the future of safer,
more effective medications.
Stay tuned.
(12:01):
The best part of this deep dive is still ahead, back again.
We've covered a lot of ground, haven't we?
Impurities, biopharmaceuticals,
ability, those manufacturing changes.
It's been a journey, but like we've mentioned,
this field is always moving forward.
Time to look ahead, see what the future holds
for impurity control.
I like that.
Looking ahead, what's got you excited?
(12:21):
Any breakthroughs on the horizon?
One thing that's really fascinating
is how analytical technology is evolving.
Scientists are creating these amazingly sensitive
instruments, you know,
ones that can detect impurities at levels
we couldn't even dream of before.
So pushing the limits of what we can see,
what we can measure.
Exactly, high resolution mass spectrometry, for example.
(12:42):
We can measure the mass of molecules
with incredible accuracy now,
find even the tiniest traces of those unwanted substances.
Like a super powered microscope,
revealing that hidden world of impurities.
Amazing.
How's that changing drug development?
Oh, it's a game changer.
Think about it.
If we can find potential impurities earlier,
(13:02):
you know, way earlier in the process,
we can make better decisions.
Optimize that whole manufacturing process
right from the start.
Precisely.
We can adjust things to minimize impurities,
reduce those risks before they even become a problem.
Like preventing the problem before it even exists.
We talked about computational modeling,
QSAR, predicting toxicity.
What else is coming down the pike there?
Computational modeling,
(13:23):
it's going way beyond just toxicity now.
Scientists are building these really sophisticated models
that can simulate the entire drug manufacturing process
from start to finish.
A virtual factory, in a way.
You could say that.
And with these simulations,
we can explore how all those different factors
in manufacturing those little variables
might affect how impurities form.
(13:43):
So, countless experiments in a computer
instead of in a real lab.
Exactly.
We can optimize the process,
minimize those impurities,
all without the time and cost of traditional experiments.
And as these models get more refined, more accurate,
they're gonna change how we approach impurity control,
make it much more proactive.
Love that.
Proactive, not reactive.
(14:05):
Speaking of global things,
what about those efforts to harmonize regulations?
We touched on that earlier.
Right, global harmonization.
Well, as the pharmaceutical industry becomes more global,
we need to have consistent standards
for drug quality and safety everywhere.
So, same rules of the game, no matter where you are.
That's the idea.
Harmonization efforts are all about
(14:25):
getting regulatory agencies from different countries
to work together, align those guidelines,
those requirements, create a more unified system, you know?
Makes a lot of sense.
And ICH is playing a big role there.
Big role, yeah.
They're bringing together experts from the industry
and those regulatory agencies to make it happen.
Building bridges, making sure those standards
are the same for everyone everywhere.
(14:47):
Exactly.
And it's not just about the agencies.
More and more people are realizing
that solving these impurity challenges,
well, it takes everyone working together.
Scientists, academia, industry, government.
All hands on deck.
Yep.
That's how we'll stay ahead of the curve, you know?
Yeah.
Anticipate those new challenges as technology changes
and we learn more about impurities.
(15:08):
It's pretty incredible when you think about it.
All this amazing potential, all this progress.
But at the end of the day, it's all about one thing.
Protecting patients.
Exactly.
This deep dive, it's taken us from the tiniest molecules
to the global stage.
But that commitment to patient health,
well, it's been the constant thread.
Couldn't agree more.
This whole journey, it's about helping people understand,
(15:30):
you know, showing them the science, the regulations,
the dedication that goes into every single medication.
I feel like I've gained a whole new appreciation for it.
That's what we hoped for.
So the next time you pick up your medication,
think about all the work, all the science
that went into making it safe.
It's really remarkable.
To wrap things up, let's recap some key points.
(15:51):
We learned that impurities, well, they're just
part of the game when it comes to pharmaceuticals.
Controlling them is absolutely essential for safety
and effectiveness.
We talked about all those guidelines,
those incredibly precise analytical tools.
How we identify those impurities, classify them,
measure them, and how the challenges can change,
depending on the type of drug we're talking about.
(16:12):
Stability testing, that was a big one.
Making sure medications stay good over time.
And how companies handle those changes in manufacturing,
make sure nothing goes wrong when they tweak things.
And of course, we looked into the future.
All those exciting new technologies,
those computer models that can predict problems
before they happen.
It's a lot to take in.
But the bottom line is this.
(16:32):
Those pharmaceutical regulations,
they might seem complicated, but they're there for a reason.
To protect patients, to make sure they
have access to the safest, most effective medications possible.
And that's what it's all about, isn't it?
Absolutely.
Thanks for joining us on this deep dive
into the world of pharmaceutical impurities.
We hope you learned something new,
(16:53):
maybe even got inspired to explore further on your own.
Keep asking questions.
There's always more to learn.
Until next time.
All right, ready to dive deep.
(00:02):
Today, it's all about pharmaceuticals,
but not the feel-good kind.
Ah, you mean the stuff we don't want in our meds.
Exactly, impurities.
We've got a great prompt from a listener
wants to unpack those ICH guidelines,
Q3A through Q3E specifically.
Great area to explore.
It's fascinating really how even a perfectly crafted drug
(00:24):
can have, you know,
these tiny bits of unwanted stuff lurking in it.
Okay, so maybe not something you want to think about
with every pill you swallow,
but crucial nonetheless, right, for safety and effectiveness.
Oh, absolutely crucial.
And that's precisely where these ICH guidelines come in.
They're like our rule book really
for making sure medications are safe
and actually do what they're supposed to do.
Okay, so rule book for impurities.
(00:45):
Let's unpack that a bit, shall we?
Yeah.
You mentioned different types of impurities.
What are we talking about here specifically?
Well, you can broadly break them down into a few categories,
organic, inorganic,
and then you've got those residual solvents.
Each one, you know, they pose their own risks
and need their own approach to control.
Makes sense.
I'm picturing, I don't know,
some heavy metal leaching into a drug from the equipment.
(01:07):
Is that a real thing that happens?
It is.
Inorganic impurities, like those heavy metals,
they often come from the manufacturing process itself.
You've also got organic impurities though,
and those might be present in the starting materials.
And then there's the whole degradation thing.
A drug can actually break down over time.
So even more potential impurities to worry about.
(01:27):
Makes you realize how complex this all is.
How do they even find these things?
That's where it gets really interesting.
You know, we're talking super precise analytical techniques
that can zero in and actually quantify these substances,
even when they're at super low levels.
So like finding a needle in a haystack,
but on a molecular level.
Pretty much.
One example is high resolution mass spectrometry.
(01:50):
Incredible tool.
Lets us measure the mass of molecules
with pinpoint accuracy,
so we can even spot tiny variations.
Could be a sign of an impurity.
Super high tech stuff.
So we found an impurity.
Now how do we know if it's a problem?
Like is there a universal too much level?
Or does it depend on the drug?
Definitely not one size fits all.
The ICH guidelines provide a framework,
(02:12):
but there are lots of factors.
Toxicity of the impurity, for example, is huge.
A highly toxic impurity is gonna have
a much lower acceptable limit.
Right, that makes sense.
What about how the drug is taken like daily
versus just once in a while?
That must factor in too.
Absolutely.
Imagine a drug taken daily for a chronic condition
versus like you said, one for a short term illness.
(02:32):
The acceptable limit for say an impurity
in that daily medication is likely gonna be way lower,
because of the longer exposure.
Okay, starting to see how this ties back to patient safety.
It's a real balancing act.
Exactly.
And that's where this concept of acceptable daily intake
comes in, ADI.
It's essentially how much of a specific substance
can be ingested daily over a lifetime without causing harm.
(02:55):
Plays a big role in setting limits.
So how do they calculate those ADIs and safety limits?
Some magic formula.
Not magic, but definitely not guesswork either.
Established methodologies, statistical models,
the whole nine yards to do a really thorough risk assessment.
Our listener actually mentioned statistical validation
in their prompt.
(03:16):
What's that mean here?
It's all about making those assessments
as reliable as we can.
Using statistical methods to analyze data,
identify trends, really build confidence
in those safety limits we're setting.
Sounds super rigorous.
Makes sense though.
Earlier you mentioned drugs breaking down over time.
How has that managed?
Stability testing is key.
(03:37):
Imagine storing samples under different conditions,
temperatures, humidity, light,
and then we analyze them over time to see how they change.
Gives us a real insight into shelf life
and how to store them properly.
Sounds meticulous.
It is, but it impacts safety directly.
A drug that goes bad quickly could be, well, dangerous.
This helps us prevent that.
(03:57):
Okay, let's switch gears for a second.
Listener also asked about purge factors.
What are those all about?
Purge factors.
They're a measure of how effectively we remove impurities
during manufacturing, like quantifying the cleaning power
of each step, you could say.
And of course we calculate and validate those carefully
to make sure the levels are safe in the end.
Interesting.
So it's like each step is a filter,
(04:18):
getting rid of more and more of those impurities.
Precisely.
Now imagine we find a brand new impurity,
something never seen before.
Gotta figure out quickly how risky it is.
That sounds tough.
It is.
That's where QSR comes in,
quantitative structure activity relationship.
QSR.
Okay, sounds a bit sci-fi.
How's that work?
(04:38):
Might sound futuristic,
but it's a real workhorse in toxicology today.
We use computer models to predict
how toxic a substance might be
just based on its chemical structure.
So instead of a ton of experiments,
you can use algorithms to get a first look.
Yep.
It's super valuable when you're dealing
with something brand new and don't have much data,
helps us prioritize.
(04:59):
Amazing.
Technology is changing the game here.
It is.
And it goes even further with all these new
software tools being developed.
They can help us define toxicological classes of impurities
so much more efficiently.
This is fascinating.
Feels like we're just getting started.
It makes you realize how much work goes into
ensuring that our meds are safe.
It's a hidden world, really,
but one that affects all of us.
(05:20):
That's what makes this deep dive so important.
Welcome back to the deep dive.
We've covered some fundamentals,
but now let's get into those real world complexities
like you mentioned.
Exactly.
Biopharmaceuticals, that's what really intrigues me.
Seems like a whole other level
when it comes to controlling impurities.
You're right, they do.
Biopharmaceuticals, you know,
those drugs derive from living organisms.
(05:43):
They tend to be much bigger, more complex molecules.
More complex than, say,
the everyday pills most of us are used to.
Exactly, and that complexity makes them, well,
more prone to a wider variety of impurities.
So we're not just talking about
simple contamination anymore.
Right.
With these biopharmaceuticals,
we've got to consider things like product-related impurities.
Basically, variations of the protein itself
(06:05):
that pop up during manufacturing.
So the protein itself can have, what, little variations?
How does that even happen?
Think of it like this.
The cells making those proteins,
they can make tiny mistakes,
and those mistakes lead to, well,
variations in the final product.
They might have slightly different structures
or some kind of modification.
So even a tiny difference could affect how the drug works.
(06:27):
Wow, how do they even find those variations?
It's like detective work at a molecular level.
We're talking advanced stuff.
Mass spectrometry, for instance,
can measure the mass of these molecules so precisely
we can see even the smallest variations.
And then there's chromatography,
separates the components of the mixture,
lets us zero in on each one.
Like a molecular jigsaw puzzle.
(06:49):
You got it.
Yeah.
And to help us solve that puzzle,
we rely on guidelines like ICH Q5A, R2, and Q6B,
specifically focused on those impurities
in biopharmaceuticals.
These guidelines are like the gift that keeps on giving.
Seems like they're behind every aspect of this process.
They are, really, and they're always evolving, too,
just like our understanding of these drugs
and the techniques we use to analyze them.
(07:10):
Makes sense.
Okay, so we found those product-related impurities,
but then there's still the stability issue, right?
They can change over time, degrade, all that.
Absolutely.
Stability is key, you know?
For any drug, really.
It has to stay safe and effective
throughout its shelf life.
Right, you wouldn't want a medication to, what,
lose its potency or become unsafe
just because it's been sitting around too long?
(07:32):
Exactly.
Yeah.
So that's where stability testing steps in.
Remember those controlled storage conditions,
different temperatures, humidity, light?
That's a big part of it.
We store the samples under those conditions
and analyze them over time, see how they change,
helps us figure out how long they're good for
and how to store them.
Sounds like a pretty involved process.
(07:52):
It is, but it's all about safety, right?
Making sure that those medications are good to go
when patients need them.
And of course, there are guidelines for that, too.
ICH Q1A, R2 is a big one, lays out the framework.
And there's also Q1F from the WHO
that specifically focuses
on active pharmaceutical ingredients.
So those guidelines keep everything consistent
and rigorous to make sure those tests are done right.
(08:12):
Right.
Ultimately, it's all about having that scientific basis
to know how long a drug is good for.
And that's absolutely critical for safety, right?
Making sure that the medications people are taking
are doing what they should be doing.
Now, what happens if a company has to make changes
to the way they manufacture a drug?
Like to make it more efficient or maybe address a problem?
(08:33):
Good question.
That's where change management comes into play.
Another key part of impurity control.
Any change, even a small one,
has the potential to affect the final product,
including its impurity profile.
Because even a small tweak could introduce something new
or change the levels, right?
How do they make sure those changes don't mess things up?
That's where ICH Q5E comes in.
(08:54):
This guideline tells us how to compare
the drug substance or product before and after a change.
The goal is to show that the final product
is essentially the same,
that it still meets those strict standards,
even with those changes.
So like comparing before and after
to see if anything went haywire?
Precisely.
We might compare physical, chemical,
even biological properties,
(09:15):
maybe do more stability studies.
Sometimes we even need new clinical trials,
depending on the change.
Wow, that's really reassuring.
It shows you how seriously they take this whole thing.
Absolutely, and that commitment to quality,
it's at the heart of what we call
a robust pharmaceutical quality system.
That's what ICH Q10 is all about.
It's not just about following the rules.
(09:35):
It's about managing quality in every aspect,
from design to manufacturing to distribution.
The goal, making sure that product quality is consistent
and patients are safe.
Like this huge interconnected system
all working together to keep patients safe.
That's a good way to put it.
And managing impurities,
well, it's a crucial part of that whole system.
Okay, we've covered a lot here.
(09:56):
Biopharmaceuticals, stability testing, managing change,
but I want to circle back to the why behind all this.
The why is always important.
Right, why does all of this matter so much?
What happens if we don't control impurities?
What are the consequences?
That's a big question,
and the answer is pretty straightforward.
Failing to control those impurities
can have serious consequences for patients.
(10:17):
It's easy to forget, right?
Yeah. These impurities are tiny.
We can't even see them, but they can have a real impact.
Exactly.
We've talked about how impurities
can affect how well a drug works,
maybe even making a condition worse.
But in some cases,
they can trigger serious unexpected side effects.
So it could be anything from a mild reaction
to something much worse.
(10:38):
Absolutely.
That's why it's so important for drug companies
and regulatory agencies to get this right.
Every step from the ingredients to the manufacturing
has to be carefully controlled
to keep those harmful impurities out of the drug supply.
It all comes back to those ICH guidelines, right?
Q3A through Q3E, making sure we can identify,
classify, and control those impurities
(10:59):
and all those incredible analytical techniques
that let us see what's really there.
Right. But it's more than just checking boxes.
It's about really understanding the science
and always striving to do better.
Always learning, always improving,
all to protect patients.
That's the key.
This deep dive, it's really pulled back the curtain
on all the science, the regulations,
(11:19):
the ethics that go into making pharmaceuticals.
It's a complex system, but it all comes down
to that commitment to patient wellbeing.
I'm with you.
It's amazing really to think about how much we've learned
about something that most people
probably never think twice about.
But as we've seen, it's incredibly important.
It is.
And as technology keeps advancing
(11:40):
and we learn more and more,
the challenges and opportunities in this field
are only going to get bigger.
That brings us to the next frontier,
the future of impurity control.
I'm excited to see what's coming next.
Me too.
In the next segment, we'll dive
into some of the most exciting developments,
stuff that's shaping the future of safer,
more effective medications.
Stay tuned.
(12:01):
The best part of this deep dive is still ahead, back again.
We've covered a lot of ground, haven't we?
Impurities, biopharmaceuticals,
ability, those manufacturing changes.
It's been a journey, but like we've mentioned,
this field is always moving forward.
Time to look ahead, see what the future holds
for impurity control.
I like that.
Looking ahead, what's got you excited?
(12:21):
Any breakthroughs on the horizon?
One thing that's really fascinating
is how analytical technology is evolving.
Scientists are creating these amazingly sensitive
instruments, you know,
ones that can detect impurities at levels
we couldn't even dream of before.
So pushing the limits of what we can see,
what we can measure.
Exactly, high resolution mass spectrometry, for example.
(12:42):
We can measure the mass of molecules
with incredible accuracy now,
find even the tiniest traces of those unwanted substances.
Like a super powered microscope,
revealing that hidden world of impurities.
Amazing.
How's that changing drug development?
Oh, it's a game changer.
Think about it.
If we can find potential impurities earlier,
(13:02):
you know, way earlier in the process,
we can make better decisions.
Optimize that whole manufacturing process
right from the start.
Precisely.
We can adjust things to minimize impurities,
reduce those risks before they even become a problem.
Like preventing the problem before it even exists.
We talked about computational modeling,
QSAR, predicting toxicity.
What else is coming down the pike there?
Computational modeling,
(13:23):
it's going way beyond just toxicity now.
Scientists are building these really sophisticated models
that can simulate the entire drug manufacturing process
from start to finish.
A virtual factory, in a way.
You could say that.
And with these simulations,
we can explore how all those different factors
in manufacturing those little variables
might affect how impurities form.
(13:43):
So, countless experiments in a computer
instead of in a real lab.
Exactly.
We can optimize the process,
minimize those impurities,
all without the time and cost of traditional experiments.
And as these models get more refined, more accurate,
they're gonna change how we approach impurity control,
make it much more proactive.
Love that.
Proactive, not reactive.
(14:05):
Speaking of global things,
what about those efforts to harmonize regulations?
We touched on that earlier.
Right, global harmonization.
Well, as the pharmaceutical industry becomes more global,
we need to have consistent standards
for drug quality and safety everywhere.
So, same rules of the game, no matter where you are.
That's the idea.
Harmonization efforts are all about
(14:25):
getting regulatory agencies from different countries
to work together, align those guidelines,
those requirements, create a more unified system, you know?
Makes a lot of sense.
And ICH is playing a big role there.
Big role, yeah.
They're bringing together experts from the industry
and those regulatory agencies to make it happen.
Building bridges, making sure those standards
are the same for everyone everywhere.
(14:47):
Exactly.
And it's not just about the agencies.
More and more people are realizing
that solving these impurity challenges,
well, it takes everyone working together.
Scientists, academia, industry, government.
All hands on deck.
Yep.
That's how we'll stay ahead of the curve, you know?
Yeah.
Anticipate those new challenges as technology changes
and we learn more about impurities.
(15:08):
It's pretty incredible when you think about it.
All this amazing potential, all this progress.
But at the end of the day, it's all about one thing.
Protecting patients.
Exactly.
This deep dive, it's taken us from the tiniest molecules
to the global stage.
But that commitment to patient health,
well, it's been the constant thread.
Couldn't agree more.
This whole journey, it's about helping people understand,
(15:30):
you know, showing them the science, the regulations,
the dedication that goes into every single medication.
I feel like I've gained a whole new appreciation for it.
That's what we hoped for.
So the next time you pick up your medication,
think about all the work, all the science
that went into making it safe.
It's really remarkable.
To wrap things up, let's recap some key points.
(15:51):
We learned that impurities, well, they're just
part of the game when it comes to pharmaceuticals.
Controlling them is absolutely essential for safety
and effectiveness.
We talked about all those guidelines,
those incredibly precise analytical tools.
How we identify those impurities, classify them,
measure them, and how the challenges can change,
depending on the type of drug we're talking about.
(16:12):
Stability testing, that was a big one.
Making sure medications stay good over time.
And how companies handle those changes in manufacturing,
make sure nothing goes wrong when they tweak things.
And of course, we looked into the future.
All those exciting new technologies,
those computer models that can predict problems
before they happen.
It's a lot to take in.
But the bottom line is this.
(16:32):
Those pharmaceutical regulations,
they might seem complicated, but they're there for a reason.
To protect patients, to make sure they
have access to the safest, most effective medications possible.
And that's what it's all about, isn't it?
Absolutely.
Thanks for joining us on this deep dive
into the world of pharmaceutical impurities.
We hope you learned something new,
(16:53):
maybe even got inspired to explore further on your own.
Keep asking questions.
There's always more to learn.
Until next time.
Popular Podcasts
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
24/7 News: The Latest
The latest news in 4 minutes updated every hour, every day.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.